Open Development and Clinical Validation Of Multiple 3D-Printed Sample-Collection Swabs: Rapid Resolution of a...

The global demand for reliable SARS-CoV-2 testing has exposed a shortage of nasopharyngeal swabs, slowing diagnostic efforts. While prior research has shown the importance of swab design for sample quality, no prior work had resolved how to rapidly produce alternatives during a pandemic. This gap motivated a collaborative effort to address the bottleneck. Existing swabs are limited in availability, and no alternative had been validated for clinical use. The urgency of the situation required a new approach. Traditional manufacturing timelines were too slow to meet the need. A solution needed to be both fast and scientifically rigorous. Open collaboration was seen as a potential route. The challenge was to develop and validate swabs within days.

This study aimed to rapidly develop and validate 3D-printed swabs as a solution to the swab shortage. The specific problem was to create a reliable alternative to standard swabs for SARS-CoV-2 testing. The motivation was to maintain diagnostic accuracy while enabling mass production. The researchers sought to prove that 3D-printed swabs could perform as well as traditional ones. They needed to test multiple designs and materials quickly. The study focused on clinical validation through comparison with a reference swab. The goal was to ensure non-inferiority in diagnostic performance. The timeline was compressed to meet urgent public health needs.

The research team designed a multi-step evaluation process for swab prototypes. Sixteen swab designs and 48 materials were tested in preclinical trials. The team collaborated with 24 contributors, including manufacturers and scientists. All results were shared publicly via a GitHub repository. Four prototypes were selected for clinical validation. The clinical trial involved 276 outpatient volunteers with suspected COVID-19 symptoms. Each participant was swabbed with a prototype and a reference swab. RT-PCR results were compared to assess diagnostic accuracy.

All four prototypes showed strong agreement with the reference swab (κ=0.85–0.89). Cycle-threshold (Ct) values were not significantly different (Mann-Whitney U p>0.05). This supports the non-inferiority of the new swabs. The prototypes performed well in terms of diagnostic sensitivity. Study staff preferred one prototype over others and the control swab. The validation process took only 22 days from problem identification. The swabs were developed using open-source methods. The results suggest that 3D-printed swabs can be a viable alternative.

The authors concluded that 3D-printed swabs can serve as a reliable alternative during shortages. The study demonstrated that these swabs are non-inferior to standard ones in terms of diagnostic accuracy. The rapid development timeline shows the potential of open collaboration. The team emphasized the importance of preclinical and clinical validation. They noted that staff preference could influence adoption in practice. The results suggest that 3D printing can be a scalable solution. The approach could be applied to future medical device needs. The authors proposed that this model could be used in other public health crises.